Trulieve reported a net loss of $403.0 million for the nine months ended September 30, 2026, primarily driven by a $403.3 million loss on a Deconsolidation Transaction. Revenue for the nine-month period decreased to $787.9 million from $888.0 million in the prior year, while cash and cash equivalents increased to $326.7 million.
Trulieve Cannabis Corp. reported Q3 2026 revenue of $230 million and positive net income of $1 million, marking a significant period following its uplisting to the NYSE. The company highlighted major regulatory milestones, including receiving final DEA registrations for medical marijuana dispensaries and the removal of 280E tax burdens.
“State licensed medical marijuana rescheduling unlocked major milestones including DEA registration, removal of 280E tax, and uplisting to the NYSE. Third quarter results demonstrate the strength of our medical cannabis platform underscored by revenue, margins, and cash generation. With meaningful growth expansion opportunities in Georgia and Texas, we are in the early stages of an accelerated growth cycle.”